Von Willebrand Disease (VWD) illustrated how real-world data can bridge the gap between symptoms and diagnosis, helping clinicians identify diagnostic delays, quantify disease burden, understand patient journeys, and generate evidence that supports more timely, personalized, and patient-centered care

Wegovy highlights of prescribing information, Novo Nordisk (2024) The risk of depression, anxiety, and suicidal behavior in patients with obesity on glucagon-like peptide-1 receptor agonist therapy, Scientific Reports (2024) Decreased risk of anxiety in diabetic patients receiving glucagon-like peptide-1 receptor agonist: A nationwide, population-based cohort study, Frontiers in Pharmacology (2022) Most GLP-1 medications correlated with a lower likelihood of anxiety and depression diagnoses, Epic Research (2024) Dopamine release in the midbrain promotes anxiety, Biological Psychology (2021) Dopamine primes the brain for enhanced vigilance, MIT News (2018) Why your cardiologist may prescribe semaglutide (Wegovy), Yale Medicine (2024) Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice
Corneal confocal microscopy: ready for prime time
It can also cause blood sugar fluctuations, leading to unwanted side effects